Bridget Lacey Appointed Chief Business Officer at Nanexa
Share price
-5.12%
Subscription
Calendar
| Est. time* | ||
| 2025-10-21 | 08:20 | Quarterly Report 2025-Q3 |
| 2025-08-27 | 08:20 | Quarterly Report 2025-Q2 |
| 2025-05-16 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2025-05-15 | - | Annual General meeting |
| 2025-05-06 | - | Quarterly Report 2025-Q1 |
| 2025-02-19 | - | Year-end Report 2024 |
| 2025-02-13 | - | Extra General Meeting 2024 |
| 2024-11-07 | - | Quarterly Report 2024-Q3 |
| 2024-08-27 | - | Quarterly Report 2024-Q2 |
| 2024-05-16 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2024-05-15 | - | Annual General meeting |
| 2024-05-03 | - | Quarterly Report 2024-Q1 |
| 2024-02-21 | - | Year-end Report 2023 |
| 2023-11-20 | - | Quarterly Report 2023-Q3 |
| 2023-08-23 | - | Quarterly Report 2023-Q2 |
| 2023-06-09 | - | Annual General meeting |
| 2023-05-30 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2023-05-04 | - | Quarterly Report 2023-Q1 |
| 2023-02-16 | - | Year-end Report 2022 |
| 2022-10-25 | - | Quarterly Report 2022-Q3 |
| 2022-08-26 | - | Quarterly Report 2022-Q2 |
| 2022-06-10 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2022-06-09 | - | Annual General meeting |
| 2022-04-20 | - | Quarterly Report 2022-Q1 |
| 2022-02-17 | - | Year-end Report 2021 |
| 2021-11-10 | - | Quarterly Report 2021-Q3 |
| 2021-08-20 | - | Quarterly Report 2021-Q2 |
| 2021-05-06 | - | Quarterly Report 2021-Q1 |
| 2021-05-03 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2021-02-18 | - | Year-end Report 2020 |
| 2020-11-12 | - | Quarterly Report 2020-Q3 |
| 2020-08-20 | - | Quarterly Report 2020-Q2 |
| 2020-06-03 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2020-06-02 | - | Annual General meeting |
| 2020-05-15 | - | Quarterly Report 2020-Q1 |
| 2020-02-28 | - | Year-end Report 2019 |
| 2019-11-12 | - | Quarterly Report 2019-Q3 |
| 2019-08-22 | - | Quarterly Report 2019-Q2 |
| 2019-06-12 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2019-06-11 | - | Annual General meeting |
| 2019-05-15 | - | Quarterly Report 2019-Q1 |
| 2019-02-20 | - | Year-end Report 2018 |
| 2018-11-12 | - | Quarterly Report 2018-Q3 |
| 2018-08-22 | - | Quarterly Report 2018-Q2 |
| 2018-05-30 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2018-05-29 | - | Annual General meeting |
| 2018-05-15 | - | Quarterly Report 2018-Q1 |
| 2018-02-20 | - | Year-end Report 2017 |
| 2017-11-10 | - | Quarterly Report 2017-Q3 |
| 2017-10-23 | - | Extra General Meeting 2017 |
| 2017-08-24 | - | Quarterly Report 2017-Q2 |
| 2017-06-13 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2017-06-12 | - | Annual General meeting |
| 2017-05-17 | - | Quarterly Report 2017-Q1 |
| 2017-02-15 | - | Year-end Report 2016 |
| 2016-11-16 | - | Quarterly Report 2016-Q3 |
| 2016-08-17 | - | Quarterly Report 2016-Q2 |
| 2016-05-27 | - | Ex-date Ordinary Dividend NANEXA 0.00 SEK |
| 2016-05-26 | - | Annual General meeting |
| 2016-05-12 | - | Quarterly Report 2016-Q1 |
| 2016-04-06 | - | Extra General Meeting 2016 |
| 2016-02-25 | - | Year-end Report 2015 |
| 2015-11-19 | - | Quarterly Report 2015-Q3 |
| 2015-08-20 | - | Quarterly Report 2015-Q2 |
Description
| Country | Sweden |
|---|---|
| List | First North Stockholm |
| Sector | Health care |
| Industry | Biotechnology |
Nanexa AB is pleased to announce the appointment of Bridget Lacey as Chief Business Officer. With over 25 years of corporate and business development experience across the life sciences sector, Bridget further strengthens Nanexa's leadership team. Bridget's role will initially be on a part-time basis.
David Westberg, CEO of Nanexa, comments, “Nanexa is in a phase where we are placing significant focus on business development. We are therefore pleased to welcome Bridget Lacey. Her extensive experience brings valuable expertise and strategic capabilities to Nanexa.”
For additional information, please contact:
David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
The company’s Certified Adviser is Carnegie Investment Bank AB (publ).
About Nanexa AB (publ)
Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.
Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).